What does cost-effective mean?
In order to evaluate the cost-effectiveness of percutaneous coronary interventions, it is important to distinguish between "costsaving" and "cost-effective". Although occasionally a new medical treatment is introduced that both improves clinical outcomes and reduces medical care costs, most medical innovations increase the cost of care. Even highly effective treatments such as bypass surgery for left main disease,2 ,B blocker therapy after myocardial infarction,3 or thrombolytic therapy for acute myocardial infarction, save lives only by increasing medical care costs. 4 Nonetheless, such treatments are generally viewed as cost-effective because their benefits are "worth the cost".'
Cost-effectiveness analysis is a formal technique that is used to maximise the health benefits available to society subject to the constraint of a fixed health care budget. By explicitly quantifying the trade-offs between health care costs and health benefits, costeffectiveness analysis allows physicians to compare the health benefits gained by use of a specific treatment to those benefits that could be achieved by alternative uses of the same health care resources. The appeal of costeffectiveness analysis for medical applications is that health benefits may be measured in any appropriate clinical unit such as lives saved, complications prevented, or years of life gained (rather than assigning monetary value to such outcomes). In the case of PTCA where both quality of life and survival are important outcome measures, health benefits are best measured in terms of quality adjusted life years (QALYs). In this framework, each year of life expectancy is weighted by a utility factor that reflects an individual's preference for his or her state of health relative to perfect health (utility = 1) and death (utility = 0).5
Once a programme's net cost and net health benefits have been evaluated, a cost-effectiveness ratio may be calculated as the ratio of these two quantities. Although there is no absolute standard for cost-effectiveness, rough thresholds may be established by comparison with cost-effectiveness ratios for other health care programmes. In general, cost-effectiveness ratios of < $20 000 per QALY gained (such as those for treatment of severe diastolic hypertension or cholesterol lowering in patients with established coronary heart disease) are viewed as highly favourable.6 Incremental cost-effectiveness ratios between $20 000 and $40 000 per QALY are also consistent with many accepted medical treatments and may be viewed as reasonably cost-effective. Cost-effectiveness ratios of > $60 000 to $80 000 are higher than most generally accepted medical treatments and are thus viewed as relatively unattractive in most medical systems.
PTCA for single vessel disease Despite its widespread adoption as an alternative to medical treatment, few studies have specifically addressed the cost-effectiveness of PTCA for patients with stable angina and single vessel coronary disease. In the only randomised trial to date, the ACME investigators found that PTCA improved both anginal symptoms and exercise tolerance compared with standard medical treatment for such patients.' Of patients assigned to medical treatment, 46% were free from angina at six months' follow up compared with 64% of those assigned to PTCA. Moreover, patients treated with initial PTCA had a greater improvement in both physical and psychological function than patients assigned to medical therapy. Not surprisingly, medical resource utilisation was also significantly greater with the PTCA strategy. Specifically, PTCA patients were hospitalised for a mean of 3-8 days during the study period compared with 2-4 days for medically treated patients, and 7% of patients assigned to PTCA required bypass surgery during follow up compared with none of the medically treated patients.
Unfortunately, no formal attempt was made to evaluate the cost-effectiveness of PTCA in the ACME trial. Coronary stenting is the only new device that has been shown to improve angiographic and clinical outcomes compared with balloon angioplasty.12 13 The resulting "stent-mania" has revolutionised the practice of interventional cardiology, but has also placed severe strains on health care reimbursement and hospital budgets in many countries. While it is clear that coronary stenting is associated with improved short and intermediate term outcomes compared with conventional PTCA, current evidence suggests that elective stenting does not pay for itself. In the economic substudy of the randomised STRESS Trial, we found that the in-hospital costs of stenting were $2200 higher than for balloon angioplasty ($9738 v $7505), yet follow up costs were only $1400 lower after stenting (fig 1 ) .14 Thus aggregate one year medical care costs remained approximately $800 higher per patient with stenting compared with conventional PTCA.
Although recent advances in stent deployment techniques, such as the use of routine high pressure post-dilatation, and the use of combined antiplatelet therapy, have further improved the safety of stenting while shortening length of stay, the net economic impact of stenting remains essentially unchanged. Several studies suggest that optimal stenting without anticoagulation remains significantly more expensive than balloon angioplasty in both the short and long term.'5 16 In a single group.bmj.com on June 25, 2017 -Published by http://heart.bmj.com/ Downloaded from centre study from Boston's Beth Israel Hospital, Sukin and colleagues found that for ideal stent lesions (single, discrete stenoses), optimal stent deployment used 20-25% more balloons and stents than did stenting in the earlier randomised trials.'5 Thus, current optimal stenting techniques have increased average catheterisation laboratory costs by nearly $600 compared with stenting as performed in the STRESS trial, and by more than $2200 compared with conventional PTCA. Thus, even if reduced anticoagulation regimens allow stenting to achieve post-procedure hospital costs identical to those for conventional angioplasty, overall one year costs should remain $600-$800 higher with stenting than with PTCA alone.
Nonetheless, it is likely that stenting-at least for discrete coronary stenoses-will eventually become cost saving relative to conventional PTCA. Such cost savings might be achieved through several mechanisms. First, the maturation of the stent market in Europe and the United States should ultimately produce significant reductions in the price of stents. Moreover, development of longer stents and stents without articulation defects should reduce procedural resource consumption as well. Finally, it is possible that optimal stent implantation or second generation stent designs will lead to further reductions in clinical restenosis and thus additional downstream cost savings compared with the STRESS results. These last possibilities are currently the subject of prospective economic evaluations in conjunction with both the Benestent II trial (in Europe) and the STRESS III registry (in the US).
Until such clinical benefits or additional inhospital cost savings are demonstrated, however, the cost-effectiveness of elective coronary stenting depends on whether its proven clinical benefits-namely a reduction in recurrent angina and the need for repeat revascularisation procedures-are sufficient to justify the additional long term costs of the procedure. To evaluate this possibility, we developed a decision-analytic model to study the long term costs and clinical effectiveness of alternative strategies for treating patients with single vessel coronary disease.'7 By updating this model to incorporate 1996 cost and outcome data, we estimate that stenting for single vessel coronary disease currently has an incremental costeffectiveness ratio of $33 700/QALY-similar to the cost-effectiveness of treating mild diastolic hypertension. Thus, the cost-effectiveness of elective coronary stenting appears to compare favourably with other medical practices.
The cost-effectiveness of coronary stenting is sensitive to several key parameters. Figure 2 demonstrates the impact of simultaneous variations in the PTCA abrupt closure and restenosis rates on the cost-effectiveness of elective stenting. If one were willing to spend up to US$40 000/QALY-similar to the costeffectiveness of treating mild hypertensionour model suggests that stenting would be cost-effective as long as the PTCA restenosis Figure 2 Plot of the relation between angiographic restenosis and abrupt closure rates, the level of acceptable cost-effectiveness, and the optimal revascularisation strategy. For combinations ofPTCA abrupt closure and restenosis rates above each threshold line, initial stenting would be preferred at that cost-effectiveness threshold, whereas angioplasty would be preferredfor those combinations below the line. 
